GlassScriptPhysician profile
Priya Phulwani
NPI 1104020031
$1,284.08
in general payments reported to CMS, 2019-2025
14 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2021: $99.39 · 2022: $42.54 · 2023: $58.26 · 2024: $609 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $307.14 | 2019-2025 | Evenity, Prolia, Prolia |
| Tolmar, INC. | $290.31 | 2024 | |
| Novo Nordisk INC | $175.46 | 2021-2025 | Ozempic |
| Abbott Laboratories | $148.44 | 2019-2022 | |
| Dexcom, INC. | $115.09 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $43.08 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2021 | |
| Neurocrine Biosciences, INC. | $32.74 | 2025 | |
| Alexion Pharmaceuticals, INC. | $28.12 | 2024 | Strensiq |
| Beta Bionics, INC. | $24.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $22.90 | 2023 | Tirosint, Licart |
| Amryt Pharma Holdings LTD | $22.30 | 2023 | Mycapssa |
| Insulet Corporation | $18.55 | 2022 | |
| Recordati_rare_diseases_inc. | $13.06 | 2023 | Signifor Lar, Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Phulwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.